Agios Pharmaceuticals Depreciation & Amortization Growth & History (AGIO)
Agios Pharmaceuticals's depreciation and amortization was $5.2M for fiscal 2025.
View full Agios Pharmaceuticals company overviewAgios Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.2M | −$500,000 | −8.77% |
| 2024 | 2024-12-31 | $5.7M | −$900,000 | −13.64% |
| 2023 | 2023-12-31 | $6.6M | −$1.8M | −21.43% |
| 2022 | 2022-12-31 | $8.4M | −$400,000 | −4.55% |
| 2021 | 2021-12-31 | $8.8M | −$600,000 | −6.38% |
| 2020 | 2020-12-31 | $9.4M | $1.3M | +16.24% |
| 2019 | 2019-12-31 | $8.1M | $915,000 | +12.76% |
| 2018 | 2018-12-31 | $7.2M | $740,000 | +11.50% |
| 2017 | 2017-12-31 | $6.4M | $724,000 | +12.68% |
| 2016 | 2016-12-31 | $5.7M | $2.4M | +70.80% |
| 2015 | 2015-12-31 | $3.3M | $2.0M | +144.48% |
| 2014 | 2014-12-31 | $1.4M | −$73,000 | −5.07% |
| 2013 | 2013-12-31 | $1.4M | $261,000 | +22.14% |
| 2012 | 2012-12-31 | $1.2M | $378,000 | +47.19% |
| 2011 | 2011-12-31 | $801,000 | — | — |
Agios Pharmaceuticals quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.4M | $91,000 | +7.23% |
| Q1 2026 | 2026-03-31 | $1.4M | — | — |
| Q4 2025 | 2025-12-31 | $1.3M | — | — |
| Q3 2025 | 2025-09-30 | $1.4M | — | — |
| Q2 2025 | 2025-06-30 | $1.3M | — | — |
| Q2 2020 | 2020-06-30 | $2.4M | $395,000 | +19.39% |
| Q1 2020 | 2020-03-31 | $2.5M | $469,000 | +23.39% |
| Q3 2019 | 2019-09-30 | $2.1M | $285,000 | +15.86% |
| Q2 2019 | 2019-06-30 | $2.0M | $298,000 | +17.14% |
| Q1 2019 | 2019-03-31 | $2.0M | $280,000 | +16.23% |
| Q3 2018 | 2018-09-30 | $1.8M | $183,000 | +11.34% |
| Q2 2018 | 2018-06-30 | $1.7M | $166,000 | +10.55% |
| Q1 2018 | 2018-03-31 | $1.7M | $134,000 | +8.42% |
| Q3 2017 | 2017-09-30 | $1.6M | $178,000 | +12.40% |
| Q2 2017 | 2017-06-30 | $1.6M | $269,000 | +20.63% |
| Q1 2017 | 2017-03-31 | $1.6M | $345,000 | +27.69% |
| Q3 2016 | 2016-09-30 | $1.4M | $389,000 | +37.15% |
| Q2 2016 | 2016-06-30 | $1.3M | $524,000 | +67.18% |
| Q1 2016 | 2016-03-31 | $1.2M | $876,000 | +236.76% |
| Q3 2015 | 2015-09-30 | $1.0M | $701,000 | +202.60% |
| Q2 2015 | 2015-06-30 | $780,000 | $453,000 | +138.53% |
| Q1 2015 | 2015-03-31 | $370,000 | $38,000 | +11.45% |
| Q3 2014 | 2014-09-30 | $346,000 | −$31,000 | −8.22% |
| Q2 2014 | 2014-06-30 | $327,000 | −$47,000 | −12.57% |
| Q1 2014 | 2014-03-31 | $332,000 | −$17,000 | −4.87% |
| Q3 2013 | 2013-09-30 | $377,000 | $58,000 | +18.18% |
| Q2 2013 | 2013-06-30 | $374,000 | — | — |
| Q1 2013 | 2013-03-31 | $349,000 | — | — |
| Q3 2012 | 2012-09-30 | $319,000 | — | — |
Agios Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Agios Pharmaceuticals's depreciation and amortization decreased from $9.4M to $5.2M, a change of −$4.2M. The latest reported quarter, Q2 2026, shows $1.4M.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Agios Pharmaceuticals source filings ↗